This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Breaking Up With Gilead Sciences

12/17/12 - 07:00 AM EST

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

read more >
Time For Common Sense Gun Control Has Arrived

12/17/12 - 06:30 AM EST

The tragedy in Newtown should bring gun owners and opponents together.

read more >
Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

12/10/12 - 09:00 AM EST

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

read more >
Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

12/03/12 - 07:00 AM EST

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

read more >
Nate Sadeghi's 2012 Biotech Stock Report Card

11/26/12 - 07:00 AM EST

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

read more >
Seattle Genetics: A Short Thesis That's Been Right And Wrong

11/12/12 - 07:00 AM EST

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

read more >
Arena Pharma Is Still A Good Short

11/05/12 - 07:00 AM EST

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

read more >
Achillion Pharma Worthy of New Look

10/31/12 - 08:16 AM EDT

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

read more >
United Therapeutics Could Lose The Battle For PAH Therapies

10/22/12 - 07:00 AM EDT

An FDA decision expected this week could easily go against United Therapeutics.

read more >
Page 1 of 5
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs